Skip to main content

Table 1 Patient Demographics in the Global aHUS Registry

From: The global aHUS registry: methodology and initial patient characteristics

Characteristic

Pediatric patientsa (n = 201)

Adult patientsa (n = 315)

Total (N = 516)

Age at enrollment, years

 Mean (SD)

8.2 (4.9)

39.7 (15.4)

27.4 (19.7)

 Median (range)

8.3 (0.0–17.9)

38.3 (18.0–81.8)

24.3 (0.0–81.8)

Age category at time of enrollment, n (%)

  <2

22 (10.9)

22 (4.3)

 2 to <5

41 (20.4)

41 (7.9)

 5 to <12

82 (40.8)

82 (15.9)

 12 to <18

56 (27.9)

56 (10.9)

 18 to <30

102 (32.4)

102 (19.8)

 30 to <40

73 (23.2)

73 (14.1)

 40 to <50

61 (19.4)

61 (11.8)

  ≥50

79 (25.1)

79 (15.3)

Female, n (%)

81 (40.3)

194 (61.6)

275 (53.3)

Race, n (%)

 Caucasian

162 (80.6)

285 (90.5)

447 (86.6)

 Other

27 (13.4)

10 (3.2)

37 (7.2)

 Black

5 (2.5)

17 (5.4)

22 (4.3)

 Asian

7 (3.5)

3 (1.0)

10 (1.9)

Country at time of enrollment, n (%)

 United States

31 (15.4)

77 (24.4)

108 (20.9)

 Germany

32 (15.9)

50 (15.9)

82 (15.9)

 United Kingdom

33 (16.4)

33 (10.5)

66 (12.8)

 Italy

20 (10.0)

45 (14.3)

65 (12.6)

 Spain

24 (11.9)

13 (4.1)

37 (7.2)

 France

3 (1.5)

25 (7.9)

28 (5.4)

 Russia

17 (8.5)

10 (3.2)

27 (5.2)

 Belgium

5 (2.5)

22 (7.0)

27 (5.2)

 Australia

2 (1.0)

24 (7.6)

26 (5.0)

 Israel

18 (9.0)

2 (0.6)

20 (3.9)

 Austria

1 (0.5)

9 (2.9)

10 (1.9)

 Canada

6 (3.0)

1 (0.3)

7 (1.4)

 United Arab Emirates

6 (3.0)

0 (0.0)

6 (1.2)

 Sweden

3 (1.5)

1 (0.3)

4 (0.8)

 Switzerland

0 (0.0)

2 (0.6)

2 (0.4)

 Finland

0 (0.0)

1 (0.3)

1 (0.2)

Year of enrollment

 2012

1 (0.5)

20 (6.3)

21 (4.1)

 2013

140 (69.7)

189 (60.0)

329 (63.8)

 2014b

60 (29.9)

106 (33.7)

166 (32.2)

Deceased, n (%)c

1 (0.5)

14 (4.4)

15 (2.9)

  1. aHUS atypical hemolytic uremic syndrome, SD standard deviation
  2. aCategorized by age at enrollment in the Registry
  3. bThrough September 30, 2014
  4. cEach of these causes of death were reported in 1 patient: acute myeloid leukemia; Aspergillus infection; cardiomyopathy; continuous gastrointestinal bleeding; gastrointestinal perforation; liver metastases; malignant cardiac arrhythmias; protracted cardiogenic shock and ventricular tachycardia; renal failure in addition to aHUS and pancreatic cancer; respiratory arrest probably due to cytomegalovirus infection; respiratory failure due to pneumonia; respiratory failure secondary to bleomycin lung injury; serious infection leading to multiple organ failure; unknown; withdrawal from dialysis and prostate cancer